Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page displays the clinical trial record, including its terminated status, study design, eligibility criteria, outcomes, locations, and record dates, instead of a 403 error response.SummaryDifference48%

- Check16 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of study details.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner appears announcing NIH website transition updates and FAQs, with a notice that federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check51 days agoChange DetectedThe study details page now displays a 403 Forbidden error in place of the content. This indicates an access restriction and prevents viewing the study record and page navigation as before.SummaryDifference0.5%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.